Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Bladder cancer remains a prevalent and lethal urinary malignancy, characterized by high recurrence rates and persistently poor prognosis for muscle-invasive disease. This clinical reality underscores the urgent need to identify modifiable risk factors. Epidemiological evidence from case-control and prospective cohort studies has established dose-dependent associations with arsenic and consistent tissue-specific accumulation of cadmium and chromium, while lead remains conditional on metabolic status. Nevertheless, substantial study heterogeneity persists, largely due to differences in exposure assessment methods, dose-response patterns, and confounding by smoking. A comprehensive synthesis integrating population-level findings with mechanistic insights remains conspicuously lacking. This review addresses this gap by critically evaluating the epidemiological associations, appraising sources of heterogeneity, and synthesizing current mechanistic understanding. The evidence points to a convergent model in which these metals trigger ROS-mediated oxidative stress and mitochondrial dysfunction as upstream initiating events, which aberrantly activate two midstream signaling branches—the ROS-dependent p38-MAPK/NF-κB and PI3K/AKT pathways promoting proliferation and survival, and the ROS-independent SUMOylation/TGF-β/Smad2/3 axis driving epithelial-mesenchymal transition. NRF2 exhibits stage-dependent duality with extensive pathway crosstalk, and these signals converge on downstream outcomes, including resistance to apoptosis, invasion, and metastasis. Beyond cancer cell-intrinsic effects, emerging evidence indicates that metal-induced signaling aberrations also remodel the tumor microenvironment through immune reprogramming, stromal activation, and metabolic shifts. Based on these insights, we propose a biomarker-guided, multi-tiered prevention framework spanning primary environmental control, secondary chemoprevention, and tertiary targeted therapy. Despite encouraging progress, critical knowledge gaps persist, particularly regarding multi-metal co-exposure, population-level mechanistic validation, and clinical translation. This review identifies these limitations and charts interdisciplinary research directions that integrate advanced exposure assessment, multi-omics, and rigorous clinical evaluation to bridge environmental exposure science and precision prevention of bladder cancer.